Skip to main content
. 2011 Oct;13(10):947–960. doi: 10.1593/neo.11024

Figure 3.

Figure 3

MZB cell depletion impairs the efficacy of the immunotherapy. (A) GL26 cells were implanted in the striatum of wild-type C57BL/6 mice. Mice were treated 14 days later with an intratumoral injection of Ad-TK+Ad-Flt3L, and as controls, with saline or an empty vector (Ad.0). At 7 and 12 days after the treatment, levels of MZB cells in the spleen were quantified by flow cytometry using anti-B220, anti-CD21, and anti-CD23 antibodies. *P < .05 versus saline, ^P < .05 versus Ad.0. (B) Representative dot plots show efficacy of MZB cell depletion in the spleen of naive mice 3, 10, and 20 days after i.p. administration of anti-CD49d antibody (100 µg) and anti-LFA-1 antibody (100 µg) or the corresponding isotype controls (rat IgG2a and rat IgG2b, 100 µg each). *P < .05 versus isotype control (two-way ANOVA). (C) GL26 cells were implanted in the striatum of C57BL/6 mice and treated 14 days later with an intratumoral injection of Ad-TK+Ad-Flt3L or saline. MZB cell depletion was performed at days 14 and 24 after tumor implantation. Kaplan-Meier survival curves show efficacy of Ad-TK+Ad-Flt3L-treated animals. *P <.05 versus saline. Mantel log-rank test.